Factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: A longitudinal study in three European cohorts

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1924-1932

  Ajeganova, S ^a,c   Humphreys, J H ^b   Verheul, M K ^c   Van Steenbergen, H W ^c   Van Nies, J A B ^c   Svensson, B ^a   Hafstrom I ^a   J Huizinga, T W ^c   Trouw, L A ^d   Verstappen, S M M ^b   Van Der Helm Van Mil, A H M ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBAMYLATED PROTEIN ANTIBODY; CITRULLINATED PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CAUSE SPECIFIC MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; EUROPEAN; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; AGED; BLOOD; EUROPE; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CAUSE OF DEATH; EUROPE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROPORTIONAL HAZARDS MODELS; RHEUMATOID FACTOR; RISK FACTORS;

EID: 84956654883     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208579     Document Type: Article

References (45)

1. Bukhari M, Lunt M, Harrison BJ, et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-12
2. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum 2000;43:1831-5
3. Mikuls TR, Saag KG, Criswell LA, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002;61:994-9
4. Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: The role of rheumatoid factor. J Rheumatol 2008;35:1009-14
5. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden J Rheumatol 1997;24:445-51
6. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis Rheumatology (Oxford) 2007;46:350-7
7. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008;58:359-69
8. Sihvonen S, Korpela M, Mustila A, et al. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:2089-94
9. Kuller LH, Mackey RH, Walitt BT, et al. Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis. Arthritis Rheum 2014;66:497-507
10. Humphreys JH, van Nies JA, Chipping J, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014;16:483
11. Ajeganova S, Andersson ML, Frostegard J, et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: A 10-year observational cohort study. J Rheumatol 2013;40:1958-66
12. López-Longo FJ, Oliver-Miñarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24
13. Thorsteinsson J, Bjornsson OJ, Kolbeinsson A, et al. A population study of rheumatoid factor in Iceland. A 5-year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 1975;7:183-94
14. Jónsson T, Thorsteinsson J, Valdimarsson H. Rheumatoid factor isotypes and cancer prognosis. Cancer 1992;69:2160-5
15. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011;108:17372-7
16. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014;73:780-3
17. Gan RW, Trouw LA, Shi J, et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis J Rheumatol 2015;42:572-9
18. Brink M, Verheul MK, Rönnelid J, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015;17:25
19. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis Arthritis Rheum 2013;65:911-15
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
21. Svensson B, Schaufelberger C, Teleman A, et al. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. Rheumatology (Oxford) 2000;39:1031-6
22. Symmons DP, Barrett EM, Bankhead CR, et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9
23. de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011;50:93-100
24. van der Helm-van Mil AH, Knevel R, van der Heijde D, et al. How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis? Rheumatology (Oxford) 2010;49:1429-35
25. Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2014;34:2706-16
26. Hjeltnes G, Hollan I, Førre Ø, et al Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol 2011;40:422-7
27. Gerli R, Bartoloni Bocci E, Sherer Y, et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:724-5
28. Marasovic-Krstulovic D, Martinovic-Kaliterna D, Fabijanic D, et al. Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? Rheumatology (Oxford) 2011;50:1505-12
29. Arnab B, Biswadip G, Arindam P, et al. Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? J Cardiovasc Dis Res 2013;4:102-6
30. Sokolove J, Brennan MJ, Sharpe O, et al. Brief report: citrullination within the atherosclerotic plaque: A potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthitis Rheum 2013;65:1719-24
31. Cambridge G, Acharya J, Cooper JA, et al. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013;228:243-6
32. Saksela E, Pyrhonen S, Timonen T, et al. Blocking effect of rheumatoid factor on the in vitro cytotoxicity of lymphoid cells from carcinoma patients. Scand J Immunol 1976;5:1075-80
33. Pyrhönen S, Timonen T, Heikkinen A, et al. Rheumatoid factor as an indicator of serum blocking activity and tumour recurrences in bladder tumours. Eur J Cancer 1976;12:87-94
34. Giuliano AE, Irie R, Morton DL. Rheumatoid factor in melanoma patients: Alterations of humoral tumor immunity in vitro. Cancer 1979;43:1624-9
35. Shmerling RH, Delbanco TL. The rheumatoid factor: An analysis of clinical utility Am J Med 1991;91:528-34
36. Shi J, van Veelen PA, Mahler M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014;13:225-30
37. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-84
38. Apostolov EO, Basnakian AG, Ok E, et al. Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. J Ren Nutr 2012;22:134-8
39. Berg AH, Drechsler C, Wenger J, et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013;5:175ra29
40. Speer T, Owala FO, Holy EW, et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 2014;35:3021-32
41. Viatte S, Plant D, Han B, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA 2015;313: 1645-56
42. van Steenbergen HW, van Nies JA, Ruyssen-Witrand A, et al. IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Res Ther 2015;17:244
43. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis Nat Genet 2012;44:291-6
44. Farragher TM, Plant D, Flynn E, et al. Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care Res 2010;62:676-82
45. van Nies JA, de Jong Z, van der Helm-van Mil AH, et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 2010;49:2210-16